138,406 Shares in Privia Health Group, Inc. $PRVA Purchased by Edgestream Partners L.P.

Edgestream Partners L.P. purchased a new stake in Privia Health Group, Inc. (NASDAQ:PRVA) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 138,406 shares of the company’s stock, valued at approximately $2,847,000.

Several other large investors have also recently bought and sold shares of the stock. State of Alaska Department of Revenue lifted its position in Privia Health Group by 1.3% during the fourth quarter. State of Alaska Department of Revenue now owns 65,747 shares of the company’s stock worth $1,558,000 after acquiring an additional 823 shares during the last quarter. PNC Financial Services Group Inc. grew its position in shares of Privia Health Group by 8.8% in the first quarter. PNC Financial Services Group Inc. now owns 10,361 shares of the company’s stock valued at $213,000 after purchasing an additional 840 shares during the last quarter. ProShare Advisors LLC grew its position in shares of Privia Health Group by 4.1% in the fourth quarter. ProShare Advisors LLC now owns 22,576 shares of the company’s stock valued at $535,000 after purchasing an additional 898 shares during the last quarter. Vanguard Personalized Indexing Management LLC increased its stake in shares of Privia Health Group by 5.9% during the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 16,250 shares of the company’s stock worth $385,000 after purchasing an additional 903 shares during the period. Finally, Hantz Financial Services Inc. increased its stake in shares of Privia Health Group by 456.2% during the fourth quarter. Hantz Financial Services Inc. now owns 1,129 shares of the company’s stock worth $27,000 after purchasing an additional 926 shares during the period. 94.48% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, CEO Parth Mehrotra sold 105,439 shares of the company’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $22.55, for a total transaction of $2,377,649.45. Following the completion of the sale, the chief executive officer directly owned 450,004 shares in the company, valued at approximately $10,147,590.20. This represents a 18.98% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO David Mountcastle sold 24,734 shares of the company’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $27.50, for a total value of $680,185.00. Following the sale, the chief financial officer owned 186,728 shares of the company’s stock, valued at approximately $5,135,020. The trade was a 11.70% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 454,580 shares of company stock worth $11,492,189 in the last 90 days. Company insiders own 5.70% of the company’s stock.

Privia Health Group Trading Down 0.8%

NASDAQ PRVA opened at $23.67 on Friday. The company has a market cap of $2.98 billion, a price-to-earnings ratio of 147.95, a PEG ratio of 1.87 and a beta of 0.83. The company has a 50 day moving average of $24.51 and a 200-day moving average of $23.35. Privia Health Group, Inc. has a 1-year low of $18.77 and a 1-year high of $28.82.

Analyst Ratings Changes

PRVA has been the subject of several research reports. Weiss Ratings raised Privia Health Group from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, July 2nd. Zacks Research cut Privia Health Group from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 7th. Citigroup reissued a “buy” rating on shares of Privia Health Group in a report on Thursday, July 23rd. Canaccord Genuity Group reduced their target price on shares of Privia Health Group from $35.00 to $34.00 and set a “buy” rating for the company in a research report on Friday, May 8th. Finally, Barclays reduced their target price on shares of Privia Health Group from $25.00 to $24.00 and set an “equal weight” rating for the company in a research report on Tuesday, May 26th. Eleven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $31.15.

Privia Health Group Company Profile

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.